NASDAQ:HZNP | Jotup

Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023

Retrieved on:

星期一, 一月 30, 2023

Biotechnology, Pharmaceutical, Health, Amgen, Pharmaceutical industry, Cryptocurrency

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its fourth-quarter and full-year 2022 financial results on Wednesday, March 1, 2023, prior to the open of U.S. financial markets.

Key Points:

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its fourth-quarter and full-year 2022 financial results on Wednesday, March 1, 2023, prior to the open of U.S. financial markets.
In light of the recently announced agreement to be acquired by Amgen Inc. and applicable securities laws, Horizon will not be hosting a conference call to discuss its financial results.
The earnings press release will be made available publicly on the Investor Relations page of its website at https://ir.horizontherapeutics.com .

Rule 15 (c) Announcement – Horizon Therapeutics plc

Retrieved on:

星期五, 一月 27, 2023

Certain capitalised words used in this announcement and not herein defined have the meanings given to such words in the announcement issued by Amgen and Horizon on December 12, 2022, pursuant to Rule 2.7 of the Irish Takeover Rules.

Key Points:

Certain capitalised words used in this announcement and not herein defined have the meanings given to such words in the announcement issued by Amgen and Horizon on December 12, 2022, pursuant to Rule 2.7 of the Irish Takeover Rules.
The directors of Amgen and Acquirer Sub accept responsibility for the information contained in this announcement other than that relating to Horizon, the Horizon group, directors of Horizon and members of their immediate families, related trusts and persons connected with them.
The directors of Horizon accept responsibility for the information contained in this announcement relating to Horizon, the Horizon group, directors of Horizon and members of their immediate families, related trusts and persons connected with them.
Horizon shareholders and investors may also obtain, without charge, a copy of the Proxy Statement (including the Scheme Document) and other relevant documents (when available) by directing a written request to Horizon Therapeutics plc, Attn: Investor Relations, 70 St. Stephen’s Green, Dublin 2, D02 E2X4, Ireland.

HORIZON THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limited Company - HZNP

Retrieved on:

星期三, 一月 25, 2023

Legal, Professional Services, Sale, AMGN, Amgen, KSF, Horizon

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Horizon Therapeutics Public Limited Company (NasdaqGS: HZNP) to Amgen Inc. (NasdaqGS: AMGN).

Key Points:

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Horizon Therapeutics Public Limited Company (NasdaqGS: HZNP) to Amgen Inc. (NasdaqGS: AMGN).
Under the terms of the proposed transaction, shareholders of Horizon will receive only $116.50 in cash for each share of Horizon that they own.
KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Rule 17 (b) Announcement – Horizon Therapeutics plc

Retrieved on:

星期一, 一月 23, 2023

Certain capitalised words used in this announcement and not herein defined have the meanings given to such words in the announcement issued by Horizon and Amgen on December 12, 2022 pursuant to Rule 2.7 of the Irish Takeover Rules.

Key Points:

Certain capitalised words used in this announcement and not herein defined have the meanings given to such words in the announcement issued by Horizon and Amgen on December 12, 2022 pursuant to Rule 2.7 of the Irish Takeover Rules.
The directors of Horizon accept responsibility for the information contained in this announcement.
on the business day following this announcement and throughout the course of the Proposed Transaction.
Neither the contents of the Horizon website nor the contents of any other website accessible from hyperlinks are incorporated into, or form part of, this announcement.

Rule 17 (a) Announcement – Horizon Therapeutics plc

Retrieved on:

星期一, 一月 23, 2023

Certain capitalised words used in this announcement and not herein defined have the meanings given to such words in the announcement issued by Horizon and Amgen on December 12, 2022 pursuant to Rule 2.7 of the Irish Takeover Rules.

Key Points:

Certain capitalised words used in this announcement and not herein defined have the meanings given to such words in the announcement issued by Horizon and Amgen on December 12, 2022 pursuant to Rule 2.7 of the Irish Takeover Rules.
The directors of Horizon accept responsibility for the information contained in this announcement.
on the business day following this announcement and throughout the course of the Proposed Transaction.
Neither the contents of the Horizon website nor the contents of any other website accessible from hyperlinks are incorporated into, or form part of, this announcement.

ALERT: The M&A Class Action Firm Continues Investigating the Merger – HZNP, ANGN, TIG, CNCE

Retrieved on:

星期三, 一月 25, 2023

Empire, Amgen, Acquisition, TIG, CNCE, CVR, Monteverde, Therapy, Security (finance), Elicio Berriz

Under the terms of the agreement, HZNP shareholders will receive $116.50 in cash per share they own.

Key Points:

Under the terms of the agreement, HZNP shareholders will receive $116.50 in cash per share they own.
It is free and there is no cost or obligation to you.
Angion Biomedica Corp. (NASDAQ: ANGN ), relating to its proposed merger with Elicio Therapeutics.
Under the terms of the agreement, TIG shareholders are expected to receive $6.15 in cash per share they own.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMRA, AGFS, SAL, HZNP

Retrieved on:

星期日, 一月 22, 2023

Amgen, Horizon Therapeutics, Advertising, NBT, Sale, Fraud, Therapy, Security (finance), Imara

If you are an Imara shareholder, click here to learn more about your rights and options .

Key Points:

If you are an Imara shareholder, click here to learn more about your rights and options .
If you are an AgroFresh shareholder, click here to learn more about your rights and options .
Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – APEN, HZNP, PSBP, TIG

Retrieved on:

星期三, 一月 18, 2023

Boston Scientific, Empire, OTC, Amgen, Monteverde, Sale, Acquisition, TIG, Security (finance)

Under the terms of the merger, APEN shareholders will receive $10.00 in cash per share they own.

Key Points:

Under the terms of the merger, APEN shareholders will receive $10.00 in cash per share they own.
It is free and there is no cost or obligation to you.
Trean Insurance Group, Inc. (NASDAQ: TIG ), relating to its proposed acquisition by affiliates of Altaris, LLC.
Under the terms of the agreement, TIG shareholders are expected to receive $6.15 in cash per share they own.

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient Populations

Retrieved on:

星期三, 一月 18, 2023

Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, European Alliance, Medicine, Dry, EULAR, Fatigue, Patient, Pain, Pharmaceutical industry, Rheumatology

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the primary endpoint was met for the second population in its Phase 2 clinical trial evaluating dazodalibep for the treatment of Sjögren’s syndrome.

Key Points:

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the primary endpoint was met for the second population in its Phase 2 clinical trial evaluating dazodalibep for the treatment of Sjögren’s syndrome.
The Phase 2 trial evaluated two patient populations and positive results in the first patient population were announced in September 2022.
Dazodalibep is the only medicine in development to achieve the primary endpoint in both patient populations in a Phase 2 trial.
All study participants were followed for at least 12 weeks after their last dose of study drug administration.

Rule 2.12 Announcement – Horizon Therapeutics plc

Retrieved on:

星期四, 一月 12, 2023

Health, Other Health, Other Science, Research, Pharmaceutical, Science, Treasury, International Securities Identification Number, Holding company, Security (finance)

In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on January 11, 2023, Horizon’s issued ordinary share capital is comprised of 228,768,464 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.

Key Points:

In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on January 11, 2023, Horizon’s issued ordinary share capital is comprised of 228,768,464 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.
The Company has 384,366 Ordinary Shares which are held as treasury shares.
The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZNP”.
The International Securities Identification Number for these securities is IE00BQPVQZ61.